Literature DB >> 30533870

Characterization of the Genome Sequences of Enterovirus C109 from Two Respiratory Disease Cases in Florida, 2016.

Terry Fei Fan Ng1, Joseph A Yglesias2, Tiffany A Stevenson-Yuen2, Caitlin M Wolfe2, Marshall R Cone2, Lea A Heberlein-Larson2, Kaija Maher1, Shannon Rogers1, Shur-Wern Wang Chern1, Anna Montmayeur3, Christina Castro4, W Allan Nix1.   

Abstract

The genomic sequences of two enterovirus C109 isolates (EV-C109 USA/FL/2016-21003 and EV-C109 USA/FL/2016-21002) were obtained during two separate case investigations of respiratory disease in two children. This marks the first description of EV-C109 genomes in the United States.

Entities:  

Year:  2018        PMID: 30533870      PMCID: PMC6211354          DOI: 10.1128/MRA.00803-18

Source DB:  PubMed          Journal:  Microbiol Resour Announc        ISSN: 2576-098X


ANNOUNCEMENT

Enterovirus species C (EV-C) members are in the Enterovirus (EV) genus in the Picornaviridae family. Currently, there are 23 types of EV-C, which are responsible for a spectrum of human diseases, including respiratory infections and central nervous system diseases. Enterovirus C109 (EV-C109) was first reported in 2010 in a Nicaraguan child with acute respiratory illness during 2008 (1) and was subsequently reported from respiratory samples in Hungary (2), Italy (3), the Netherlands (4), and Denmark (5), as well as from fecal specimens in the Republic of the Congo (6). Currently, only two published sequences contain the complete coding region; these are the prototype strain (Nicaragua/2008, GenBank accession no. GQ865517) and a Hungarian strain (Hungary/2007, GenBank accession no. JN900470). During February and June of 2016, we investigated two separate cases of respiratory disease in two children from Florida, both aged 5 years, with symptoms of fever, cough, and sore throat. Samples from both children were submitted to the Bureau of Public Health Laboratories Tampa Laboratory as outpatient surveillance submissions from the Influenza Incidence Surveillance Program. Nucleic acids extracted from nasopharyngeal (NP) swabs tested positive for enterovirus using pan-enterovirus real-time reverse transcription-PCR (7). Sanger sequencing targeting the VP1 region (8) identified EV-C109 in both patients, the first two cases detected in the United States. We obtained full genomic sequences of EV-C109 using published protocols (9, 10); in brief, we performed random reverse transcription and PCR amplification, followed by Nextera XT (Illumina) library production and MiSeq reagent V2 (Illumina) sequencing (9). Bioinformatics analysis was conducted with an in-house next-generation sequencing (NGS) pipeline (10). The NGS efficiency (viral reads/total reads) was 7 to 42%; as expected, the efficiency is lower for an NP specimen than for an EV culture (10). The de novo assembly efficiency metric UG50% (a metric for comparing assembly results from different samples or studies) (11) was 100%, demonstrating direct full-genome assembly. EV-C109 USA/FL/2016-21002 and EV-C109 USA/FL/2016-21003 (GenBank accession no. MH128992 and MH128993, respectively) are 7,336 and 7,327 nucleotides long, respectively. Compared to the prototype, these two genomes are complete in the 3' nontranslated region (NTR) and missing 17 to 28 nucleotides from the 5' NTR. Our EV-C109 genomes from 2016 share 98% genome-wide nucleotide identity (NI) with each other; they share 92% NI with the prototype (Nicaragua/2008, GQ865517) and the Hungarian strain (Hungary/2007, JN900470). Complete VP1 sequences from the Florida/2016 strains share higher NI with each other (98%) than with recent Danish strains (97%; Denmark/2015, GenBank accession no. KX901640) or to the earlier Hungarian and Nicaraguan strains (91 to 93%). Comparisons of the polyprotein and VP1 regions showed that the two Florida/2016 strains share high amino acid identity (AI) (99.5% polyprotein; 99.7% VP1) with each other and slightly lower AI with the two reference strains (98.2 to 98.5% for polyprotein and 97.0% to 98.0% for VP1). Comparison of the VP1 region of both strains to that of the prototype Nicaragua/2008 showed nonsynonymous substitutions of V25A, S140G, C144S, C145S, and N281K. The prototype EV-C109 genome was first identified as an EV-C strain harboring a 5' NTR most closely related to an enterovirus A (EV-A) 5' NTR (1), which is attributed to undated recombination events between ancestral strains of both species. The Florida/2016 strains contain no detectable recombinant sites compared to Nicaragua/2008 and Hungary/2007.

Data availability.

The sequences of EV-C109 USA/FL/2016-21002 and EV-C109 USA/FL/2016-21003 have been deposited in GenBank under accession no. MH128992 and MH128993, respectively.
  11 in total

1.  Comparative evaluation of Taqman real-time PCR and semi-nested VP1 PCR for detection of enteroviruses in clinical specimens.

Authors:  M Steven Oberste; Silvia Peñaranda; Shannon L Rogers; Elizabeth Henderson; W Allan Nix
Journal:  J Clin Virol       Date:  2010-07-27       Impact factor: 3.168

2.  Sensitive, seminested PCR amplification of VP1 sequences for direct identification of all enterovirus serotypes from original clinical specimens.

Authors:  W Allan Nix; M Steven Oberste; Mark A Pallansch
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

3.  An enhanced Enterovirus surveillance system allows identification and characterization of rare and emerging respiratory enteroviruses in Denmark, 2015-16.

Authors:  Céline Barnadas; Sofie E Midgley; Marianne N Skov; Lotte Jensen; Mille W Poulsen; Thea Kølsen Fischer
Journal:  J Clin Virol       Date:  2017-05-29       Impact factor: 3.168

4.  High-Throughput Next-Generation Sequencing of Polioviruses.

Authors:  Anna M Montmayeur; Terry Fei Fan Ng; Alexander Schmidt; Kun Zhao; Laura Magaña; Jane Iber; Christina J Castro; Qi Chen; Elizabeth Henderson; Edward Ramos; Jing Shaw; Roman L Tatusov; Naomi Dybdahl-Sissoko; Marie Claire Endegue-Zanga; Johnson A Adeniji; M Steven Oberste; Cara C Burns
Journal:  J Clin Microbiol       Date:  2016-12-07       Impact factor: 5.948

5.  A metagenomics and case-control study to identify viruses associated with bovine respiratory disease.

Authors:  Terry Fei Fan Ng; Nikola O Kondov; Xutao Deng; Alison Van Eenennaam; Holly L Neibergs; Eric Delwart
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

6.  Type 1 wild poliovirus and putative enterovirus 109 in an outbreak of acute flaccid paralysis in Congo, October-November 2010.

Authors:  G Grard; J F Drexler; S Lekana-Douki; M Caron; A Lukashev; D Nkoghe; J P Gonzalez; C Drosten; E Leroy
Journal:  Euro Surveill       Date:  2010-11-25

7.  U50: A New Metric for Measuring Assembly Output Based on Non-Overlapping, Target-Specific Contigs.

Authors:  Christina J Castro; Terry Fei Fan Ng
Journal:  J Comput Biol       Date:  2017-04-18       Impact factor: 1.479

8.  Human enterovirus 109 (EV109) in acute paediatric respiratory disease in Hungary.

Authors:  Péter Pankovics; Akos Boros; Hajnalka Szabó; Gyöngyi Székely; Kálmán Gyurkovits; Gábor Reuter
Journal:  Acta Microbiol Immunol Hung       Date:  2012-06       Impact factor: 2.048

9.  Newly Identified Enterovirus C Genotypes, Identified in the Netherlands through Routine Sequencing of All Enteroviruses Detected in Clinical Materials from 2008 to 2015.

Authors:  Coretta C Van Leer-Buter; Randy Poelman; Renze Borger; Hubert G M Niesters
Journal:  J Clin Microbiol       Date:  2016-06-29       Impact factor: 5.948

10.  Epidemiological, molecular and clinical features of enterovirus 109 infection in children and in adult stem cell transplant recipients.

Authors:  Maurizia Debiaggi; Elisa Rita Ceresola; Michela Sampaolo; Emilio Paolo Alessandrino; Roberto Brerra; Aurora Piazza; Massimo Clementi; Filippo Canducci
Journal:  Virol J       Date:  2012-09-04       Impact factor: 4.099

View more
  1 in total

1.  Epidemiology and clinical manifestations of different enterovirus and rhinovirus types show that EV-D68 may still have an impact on severity of respiratory infections.

Authors:  Simon B Larsson; Diana Vracar; Marie Karlsson; Johan Ringlander; Heléne Norder
Journal:  J Med Virol       Date:  2022-04-18       Impact factor: 20.693

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.